Brief Research Report

Published on 10 May 2024

Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients

in Pharmacology of Anti-Cancer Drugs

Takeru Kashiwada
Ryotaro Takano
Fumihiko Ando
Shoko Kuroda
Yoshishige Miyabe
Ryuji Owada
Akihiko Miyanaga
Tomoko Asatsuma-Okumura
Masaaki Hashiguchi
Yoshikazu Kanazawa

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1384733

127 views

Systematic Review

Published on 10 May 2024

A comprehensive bibliometric analysis (2000–2022) on the mapping of knowledge regarding immunotherapeutic treatments for advanced, recurrent, or metastatic cervical cancer

in Pharmacology of Anti-Cancer Drugs

Yuanqiong Duan
Lin Yang
Wenxiang Wang
Peixuan Zhang
Kaiyu Fu
Wen Li
Rutie Yin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1351363

169 views

Original Research

Accepted on 09 May 2024

Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: A meta-analysis and trial sequential analysis of randomized controlled trials

in Pharmacology of Anti-Cancer Drugs

Yao Xie
Fei Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1423891

Review

Accepted on 09 May 2024

Unravelling Cancer Progression Pathways and Phytochemical Therapeutic Strategies for its Management

in Pharmacology of Anti-Cancer Drugs

Vikas Sharma
Anis Chaudhary
Shweta Bawari
Dr Saurabh Gupta
Richa Mishra
Salah-Ud-Din Khan
Mohamed A. M. Ali
Mohammad Shahid
Saurabh Srivastava
Devvret Verma

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1414790

Original Research

Accepted on 09 May 2024

IL-23 inhibitor enhances the effects of PTEN DNA-loaded lipid nanoparticles for metastatic CRPC therapy

in Pharmacology of Anti-Cancer Drugs

Xinlu Chen
Luyao Gong
Yuanyuan Wang
Chen Ye
Huanhuan Guo
Jiyuan Chen
Shen Gao
Zhuo Wang
Yuan Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1388613

Original Research

Accepted on 09 May 2024

IL4I1: A Novel Molecular Biomarker represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer

in Pharmacology of Anti-Cancer Drugs

Xiangrong Peng
Chuan Liu
Li Zhang
Yin Chen
Lixin Mao
Shenglin Gao
Xiaokai Shi
Li Zuo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1365683

Opinion

Published on 09 May 2024

Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup

in Pharmacology of Anti-Cancer Drugs

Jianghua Ding
Shengping Gong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1398879

Review

Published on 09 May 2024

Ferroptosis: emerging roles in lung cancer and potential implications in biological compounds

in Pharmacology of Anti-Cancer Drugs

Qiuran Liang
Yuehui Wang
Yili Li
Jinyan Wang
Chuanbo Liu
Yicong Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1374182

119 views

Review

Published on 09 May 2024

Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer

in Pharmacology of Anti-Cancer Drugs

Feizhi Lin
Yongming Chen
Bowen Huang
Shenghang Ruan
Jun Lin
Zewei Chen
Chunyu Huang
Baiwei Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1391562

159 views

Systematic Review

Published on 09 May 2024

Application and potential value of curcumin in prostate cancer: a meta-analysis based on animal models

in Pharmacology of Anti-Cancer Drugs

Shiheng Wang
Fengxia Zhang
Jing Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1379389

Case Report

Accepted on 08 May 2024

QL1604 combined with bevacizumab as an innovative first-line treatment for HCC patient with extensive metastasis who showed remarkable effect：a case report.

in Pharmacology of Anti-Cancer Drugs

Yanzhi Wan
hong Zhu
Tan Keqin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1364871

Original Research

Accepted on 08 May 2024

Proteomic Profiling and Biomarker Discovery for Predicting Response to PD-1 Inhibitor Immunotherapy in Gastric Cancer Patients

in Pharmacology of Anti-Cancer Drugs

Jiangang Sun
Xiaojing Li
Qian Wang
Peng Chen
Longfei Zhao
Yongshun Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1349459

Original Research

Accepted on 08 May 2024

The value of plasma omega-3 polyunsaturated fatty acids in predicting the response and prognosis of cervical squamous cell carcinoma patients to concurrent chemoradiotherapy

in Pharmacology of Anti-Cancer Drugs

鹏彬平
Juan Li
Xiaoying Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1379508

Original Research

Accepted on 08 May 2024

Integrated pan-cancer analysis reveals the immunological and prognostic potential of RBFOX2 in human tumors

in Pharmacology of Anti-Cancer Drugs

Fengxian Huang
Long Jin
Xinyue Zhang
Min Wang
Congya Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1302134

Editorial

Published on 08 May 2024

Editorial: Targeting ion homeostasis for cancer therapy: mechanisms and immunomodulatory effects

in Pharmacology of Anti-Cancer Drugs

Xuemei Zeng
Zhenglin Li
Zhiyao Yi
Shuangqian Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1418700

121 views

Original Research

Published on 07 May 2024

Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer

in Pharmacology of Anti-Cancer Drugs

Fumihiko Ando
Takeru Kashiwada
Shoko Kuroda
Takenori Fujii
Ryotaro Takano
Yoshishige Miyabe
Shinobu Kunugi
Takashi Sakatani
Akihiko Miyanaga
Tomoko Asatsuma-Okumura

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1384731

232 views

Navigation group

Articles

Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients

A comprehensive bibliometric analysis (2000–2022) on the mapping of knowledge regarding immunotherapeutic treatments for advanced, recurrent, or metastatic cervical cancer

Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: A meta-analysis and trial sequential analysis of randomized controlled trials

Unravelling Cancer Progression Pathways and Phytochemical Therapeutic Strategies for its Management

IL-23 inhibitor enhances the effects of PTEN DNA-loaded lipid nanoparticles for metastatic CRPC therapy

IL4I1: A Novel Molecular Biomarker represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer

Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup

Ferroptosis: emerging roles in lung cancer and potential implications in biological compounds

Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer

Application and potential value of curcumin in prostate cancer: a meta-analysis based on animal models

QL1604 combined with bevacizumab as an innovative first-line treatment for HCC patient with extensive metastasis who showed remarkable effect：a case report.

Proteomic Profiling and Biomarker Discovery for Predicting Response to PD-1 Inhibitor Immunotherapy in Gastric Cancer Patients

The value of plasma omega-3 polyunsaturated fatty acids in predicting the response and prognosis of cervical squamous cell carcinoma patients to concurrent chemoradiotherapy

Integrated pan-cancer analysis reveals the immunological and prognostic potential of RBFOX2 in human tumors

Editorial: Targeting ion homeostasis for cancer therapy: mechanisms and immunomodulatory effects

Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer